Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and reported Q1 2025/26 results for the quarter ended Sept 30, 2025. Key operational progress includes advancing PRP toward a planned Phase 1b first-in-human study in 30–40 patients in 2026, GMP manufacturing scale-up with purification achieving >95% purity, and Rec-PRP synthetic program moving to formal preclinical development after potency evaluation. IP activity includes multiple patent drafts and a proposed 12‑month extension of the POP1 research program with Universities of Jaén and Granada. Financings: a closed underwritten public offering of 1,000,000 shares at $4.00 ($4.0M gross), Nasdaq trading began Aug 15, 2025, and a $100M private placement facility with an initial $1M tranche received. Quarter-end cash was $600,000 with total current assets of $17M.

Positive

• Planned Phase 1b PRP trial in 2026 for 30–40 patients
• GMP scale-up delivering >95% purity for PRP
• Closed public offering: $4.0M gross proceeds
• Nasdaq trading commenced on Aug 15, 2025
• Signed private placement facility up to $100M with $1M initial tranche

Negative

• Quarter-end cash of only $600,000
• Net cash from financing needed: $2.53M reported this quarter

Insights

Clinical and Corporate Analyst

Progress toward a Phase 1b trial, Nasdaq listing, and new financing materially advance development but near-term cash is tight.

Propanc Biopharma is advancing its lead candidate PRP toward a planned Phase 1b first‑in‑human study in 2026, reporting successful GMP scale-up and >95% purity for the drug substance, and ongoing Investigator’s Brochure and Clinical Trial Application preparations. The company also describes a synthetic program (Rec‑PRP) entering preclinical development after potency evaluation, and an extension negotiation for the POP1 academic research program tied to additional patent filings.

The corporate position shows meaningful financing progress: a closed public offering of 1,000,000 shares at $4.00 per share raising $4,000,000, Nasdaq trading commencement on Aug 15, and a $100,000,000 private placement facility with an initial $1,000,000 tranche received. At quarter end the company reported total current assets of $17,000,000, net cash from financing activities of $2,530,000, and $600,000 in cash; current liabilities were reduced by $2,000,000.

Key dependencies and near‑term risks include completion of the Clinical Trial Application and regulatory acceptance required to start the 2026 Phase 1b study, biological comparability and potency results for Rec‑PRP before formal preclinical entry, and the availability and timing of further tranches from the private placement facility to fund operations. Monitor the next material milestones: Clinical Trial Application filing and acceptance, Rec‑PRP potency validation, receipt schedule for additional tranches under the $100,000,000 facility, and updated cash balance over the next fiscal quarters.

MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30).

Corporate and R&D Highlights

Advancing PRP Toward Phase 1b First-in-Human Trial (2026)

Propanc continues to advance its lead candidate, PRP, toward a world-first Phase 1b clinical study in 30–40 patients with advanced solid tumors at the Peter Mac Cancer Center in Melbourne. GMP manufacturing scale-up, analytical method validation, and preparation of the Investigator’s Brochure and Clinical Trial Application are underway. Purification processes have been successfully scaled, delivering >95% purity to pharmaceutical standards. Two related patents are in drafting.

Progressing Rec-PRP Synthetic Program

Rec-PRP, a fully synthetic recombinant version of PRP designed for improved stability and global scalability, is undergoing biological validation against the bovine-derived formulation. Supporting research has identified methods enabling large-scale production, with patent drafting in progress. Rec-PRP will enter formal preclinical development following potency evaluation.

POP1 Joint Research Program Extension        

Propanc is negotiating a 12-month extension with the Universities of Jaén and Granada to expand the POP1 research program. Recent findings show PRP significantly reduces tumorigenicity in Gemcitabine-resistant pancreatic cancer and modulates malignant cells toward a less aggressive phenotype. Additional patents are being prepared based on these results.

Corporate and Financial Updates

Nasdaq Listing & Public Offering

The Company closed an underwritten public offering of 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 million. Propanc’s common stock began trading on the Nasdaq Capital Market on August 15.

$100 Million Private Placement Facility

Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1 million investment upon issuance of 100 shares of Series C Convertible Preferred Stock.

Q1 Financial Summary (Quarter Ended September 30, 2025)

• Total current assets: $17 million
• Total current liabilities reduced by $2 million
• Net cash from financing activities: $2.53 million
• Quarter-end cash: $600,000
• $1 million initial tranche from the Series C facility subsequently received

The Company expects the financing facility to support planned R&D activities, including advancement of PRP and Rec-PRP.

Management Commentary

“Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” said James Nathanielsz, CEO of Propanc. “We are focused on initiating the Phase 1b PRP clinical trial, advancing Rec-PRP into preclinical development, and expanding our IP portfolio. With our recent Nasdaq uplisting and long-term financing facility, we are well-positioned to accelerate commercialization of our proenzyme technology.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

CONDENSED CONSOLIDATED BALANCE SHEETS
	September 30, 2025				June 30, 2025
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	602,737			$	12,088
GST tax receivable		8,383				5,302
Prepaid expenses - current portion		8,143,532				8,334,046
Other current assets		8,828				1,380
TOTAL CURRENT ASSETS		8,763,480				8,352,816
Deferred offering costs		15,000				291,773
Prepaid expenses - long-term portion		9,136,572				10,925,835
Security deposit - related party		1,986				1,971
Operating lease right-of-use assets, net - related party		56,279				59,413
Property and equipment, net		2,364				-
TOTAL ASSETS	$	17,975,681			$	19,631,808
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	1,072,108			$	1,249,596
Accrued expenses and other payables		842,154				1,486,550
Accrued interest		150,443				190,795
Loans payable		65,280				65,280
Loans payable - related parties, net of discount		460,240				415,329
Notes payable, net of discount		-				543,312
Convertible notes, net of discounts and including put premiums		106,968				537,921
Operating lease liability - related party, current portion		20,500				17,664
Embedded conversion option liabilities		167,878				403,892
Employee benefit liability		686,863				667,901
TOTAL CURRENT LIABILITIES		3,572,434				5,578,240
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount		-				105,627
Operating lease liability - long-term portion - related party		42,080				41,749
TOTAL NON-CURRENT LIABILITIES		42,080				147,376
TOTAL LIABILITIES	$	3,614,514			$	5,725,616
Commitments and Contingencies (See Note 8)
STOCKHOLDERS' EQUITY:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of September 30, 2025 and June 30, 2025	$	-			$	-
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of September 30, 2025 and June 30, 2025		-				-
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 12,806,748 and 11,611,782 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively		12,807				11,612
Common stock issuable (518,687 and 7,750 shares as of September 30, 2025 and June 30, 2025, respectively)		519				8
Additional paid-in capital		143,517,615				138,243,652
Accumulated other comprehensive income		1,335,961				1,318,917
Accumulated deficit		(130,459,258	)			(125,621,520	)
Treasury stock ($0.001 share)		(46,477	)			(46,477	)
TOTAL STOCKHOLDERS' EQUITY		14,361,167				13,906,192
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	17,975,681			$	19,631,808

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
	For the three months ended September 30,
		2025				2024
REVENUE
Revenue	$	-			$	-
OPERATING EXPENSES
Administration expenses		4,598,574				220,759
Occupancy expenses - related party		14,789				8,317
Research and development		60,201				61,714
TOTAL OPERATING EXPENSES		4,673,564				290,790
LOSS FROM OPERATIONS		(4,673,564	)			(290,790	)
OTHER INCOME (EXPENSE)
Interest expense		(305,649	)			(86,230	)
Interest income		19				1
Derivative expense		-				(27,182	)
Change in fair value of derivative liabilities		(19,706	)			52,787
Gain (loss) on extinguishment of debt, net		195,861				(11,319	)
Foreign currency transaction gain (loss)		(34,699	)			8,423
TOTAL OTHER INCOME (EXPENSE), NET		(164,174	)			(63,520	)
LOSS BEFORE TAXES		(4,837,738	)			(354,310	)
Tax benefit		-				-
NET LOSS	$	(4,837,738	)		$	(354,310	)
BASIC AND DILUTED NET LOSS PER SHARE	$	(0.39	)		$	(35.97	)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING		12,331,526				9,849
NET LOSS	$	(4,837,738	)		$	(354,310	)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)		17,044				(98,943	)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)		17,044				(98,943	)
TOTAL COMPREHENSIVE LOSS	$	(4,820,694	)		$	(453,253	)
The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

FAQ

What clinical milestone did Propanc (PPCB) announce for 2026?

Propanc plans a world-first Phase 1b PRP trial in 30–40 patients in 2026 at Peter Mac Cancer Center.

How much did Propanc (PPCB) raise in its recent public offering?

The company closed an underwritten offering of 1,000,000 shares at $4.00, raising $4.0M gross.

What financing facility did Propanc (PPCB) secure to support clinical development?

Propanc entered a private placement facility for up to $100M and received an initial $1M tranche.

What were Propanc's reported cash and current assets at Sept 30, 2025?

Quarter-end cash was $600,000 and total current assets were reported at $17M.

What manufacturing progress did Propanc report for PRP (PPCB)?

GMP manufacturing scale-up and purification reached pharmaceutical standards with >95% purity.

When did Propanc (PPCB) begin trading on Nasdaq?

Propanc's common stock began trading on the Nasdaq Capital Market on Aug 15, 2025.